Methods for treating hair loss disorders

Patent metadata

Field	Value
Publication number	US-12138490-B2
Application number	US-202217714964-A
Country	US
Kind code	B2
Filing date	Apr 6, 2022
Priority date	Nov 2, 2010
Publication date	Nov 12, 2024
Grant date	Nov 12, 2024

Abstract

The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

First claim

What is claimed is:

1. A method of treating alopecia areata in a human subject in need thereof, the method consisting of orally administering to the human subject an effective amount of a small molecule JAK3 inhibitor, wherein the alopecia areata in the human subject is treated.

2. The method of claim 1 , wherein the small molecule JAK3 inhibitor is selected from Janex 1 (WHI-P131), PF-956980, WHI-P154, tofacitinib (CP690550), VX-509, JAK3 Inhibitor IV (ZM-39923), NSC114792, R348, a pharmaceutically acceptable salt thereof, and a combination thereof.

3. The method of claim 1 , wherein the alopecia areata is selected from patchy alopecia areata, alopecia totalis, and alopecia universalis.

4. The method of claim 1 , wherein the JAK3 inhibitor is administered in a pharmaceutical composition selected from the group consisting of a solution, suspension, capsule, tablet, pill, and troche.

5. The method of claim 1 , wherein administering to the human subject occurs daily.

6. The method of claim 1 , wherein treatment is inducing hair growth.

7. The method of claim 1 , wherein the human subject is an adult.

8. The method of claim 1 , wherein the human subject is a child.

9. The method of claim 7 , wherein the effective amount is about 1 mg/kg body weight of the human subject.

10. The method of claim 7 , wherein the effective amount is selected from about 450 μg/kg body weight of the human subject, about 500 μg/kg body weight of the human subject, about 550 μg/kg body weight of the human subject, about 600 μg/kg body weight of the human subject, about 650 μg/kg body weight of the human subject, about 700 μg/kg body weight of the human subject, about 750 μg/kg body weight of the human subject, about 800 μg/kg body weight of the human subject, about 850 μg/kg body weight of the human subject, about 900 μg/kg body weight of the human subject and about 950 μg/kg body weight of the human subject.

11. The method of claim 7 , wherein treatment is inducing hair growth.

12. A method of treating severe alopecia areata in a human subject in need thereof, the method consisting of orally administering once daily to the human subject an effective amount of a small molecule JAK3 inhibitor, wherein the alopecia areata in the human subject is treated.

13. The method of claim 12 , wherein the small molecule JAK3 inhibitor is selected from Janex 1 (WHI-P131), PF-956980, WHI-P154, tofacitinib (CP690550), VX-509, JAK3 Inhibitor IV (ZM-39923), NSC114792, R348, a pharmaceutically acceptable salt thereof, and a combination thereof.

14. The method of claim 12 , wherein the severe alopecia areata is selected from alopecia totalis and alopecia universalis.

15. The method of claim 12 , wherein the human subject is an adult.

16. The method of claim 12 , wherein the human subject is a child.

Assignees

• Univ Columbia

Inventors

• Christiano Angela M
• Clynes Raphael

Classifications

• A61K2800/782

  Enzyme inhibitors; Enzyme antagonists · CPC title

• A61K31/553

  having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• A61K31/529

  forming part of bridged ring systems · CPC title

• A61K31/437

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title